Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

Abstract: A coated substrate is disclosed, including a solvent-sensitive substrate and a polyester coating disposed on the solvent-sensitive substrate, wherein the polyester coating includes a polyester copolymer of a polyol and a polyacid. A method for forming a coated substrate is disclosed including spraying solvated polyester material from a spray nozzle onto a solvent-sensitive substrate and drying the solvated polyester material to form a polyester disposed on the solvent-sensitive substrate, wherein the solvated polyester material and the polyester coating include a polyester copolymer of a polyol and a polyacid.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A first process includes suturelessly fixing a surface-modified polyester textile to Nitinol wire. The surface-modified polyester textile includes a textile of a polyester having a modified surface that provides surface crosslinkable groups. A first composition includes a Nitinol layer, a passivation layer bound to the Nitinol layer, a surface-modified polyester layer, and a tie layer binding the surface-modified polyester layer to the passivation layer. A first implantable device includes a Nitinol wire, a passivation layer bound to the Nitinol wire, a surface-modified polyester textile, and a tie layer binding the surface-modified polyester textile to the passivation layer such that the surface-modified polyester textile is suturelessly fixed to the Nitinol wire. A second implantable device and a second composition include a polymer of glycerol and sebacic acid including a catechol group. A second process includes forming a polymer of glycerol and sebacic acid including a catechol group.

Abstract: A first process produces poly(glycerol sebacate) urethane (PGSU)-based microparticles. The first process includes forming a first composition including a poly(glycerol sebacate) (PGS) resin and dispersing the first composition in a continuous fluid phase in the presence of an isocyanate crosslinker to produce PGSU-based microparticles. A second process also produces PGSU-based microparticles. The second process includes forming a first composition including a PGS resin, forming a second composition and combining the first composition and the second composition to produce PGSU-based microparticles, where at least one of the first and the second composition includes an isocyanate crosslinker.

Abstract: A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.

Abstract: A cryopreservation process includes combining a cryopreservation composition with a biological sample. The cryopreservation composition includes at least one glycerol ester component. The cryopreservation process also includes then cooling the cryopreservation composition with the biological sample to a cryopreservation temperature. The cryopreservation composition aids in cryopreserving the biological sample at the cryopreservation temperature. A cryopreservation composition includes at least one glycerol ester component. A cryopreserved system includes a biological sample in a cryopreservation composition at a cryopreservation temperature. The cryopreservation composition includes at least one glycerol ester component.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A leaflet for a heart valve replacement includes poly(glycerol sebacate) urethane. A heart valve replacement includes a leaflet including poly(glycerol sebacate) urethane. A process forms a leaflet for a heart valve replacement. The process includes casting a first solution including poly(glycerol sebacate) and isocyanate to form a leaflet composition including poly(glycerol sebacate) urethane. The process also includes shaping the leaflet composition to form the leaflet.

Abstract: A manufacturing process includes combining a liquid resin with a liquid reactive cross-linking composition to form a reactive core composition. The manufacturing also includes contacting the reactive core composition with a sheath composition including a carrier polymer in a solvent. The manufacturing process further includes wet spinning the reactive core composition with the sheath composition to form a sheath-core fiber including a core including at least one continuous fiber of a reaction product of the liquid resin and liquid cross-linking composition and a sheath surrounding the core. The cross-linking composition reacts with the resin during the wet spinning. The sheath includes the carrier polymer. A continuous poly(glycerol sebacate) urethane (PGSU) fiber comprising PGSU and a continuous PGSU fiber forming system are also disclosed.

Abstract: A delivery system is described that includes a controlled release device that includes a crosslinked poly(glycerol sebacate) (PGS) or other glycerol ester and a controlled release compound, the controlled release device being provided in a contracted state and being expandable to a three-dimensional expanded state in a target location. The delivery systems provides an expandible, flexible biodegradable elastomer loaded with an active ingredient to allow for extended release for different dosage forms for either human or animal health products in vivo, delivered through the gastrointestinal tract.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A method of forming a skin care product includes combining at least one additive including at least one active ingredient with at least one glycerol-sebacate component having repeating units of (glycerol sebacate), water, a co-solvent, and at least one of an emulsifier, a surfactant, and a bodying agent to form the skin care product. A dermocosmetic composition includes at least one additive including at least one active ingredient and at least one glycerol-sebacate component having repeating units of (glycerol sebacate). A method of skin care includes applying a dermocosmetic composition to a skin surface.

Abstract: A method of forming a skin care product includes combining at least one additive including at least one active ingredient with at least one glycerol-sebacate component having repeating units of (glycerol sebacate), water, a co-solvent, and at least one of an emulsifier, a surfactant, and a bodying agent to form the skin care product. A dermocosmetic composition includes at least one additive including at least one active ingredient and at least one glycerol-sebacate component having repeating units of (glycerol sebacate). A method of skin care includes applying a dermocosmetic composition to a skin surface.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.

Abstract: A method of forming a skin care product includes combining at least one additive including at least one active ingredient with at least one glycerol-sebacate component having repeating units of (glycerol sebacate), water, a co-solvent, and at least one of an emulsifier, a surfactant, and a bodying agent to form the skin care product. A dermocosmetic composition includes at least one additive including at least one active ingredient and at least one glycerol-sebacate component having repeating units of (glycerol sebacate). A method of skin care includes applying a dermocosmetic composition to a skin surface.

Abstract: The disclosure describes textiles for endovascular and other medical applications having a low-profile and varying density. The textiles are woven and are formed of a non-uniform construction. The resulting textiles have a low profile and areas of targeted density to enhance ingrowth of regenerative tissue.

Abstract: This invention is a bottle-mounted greeting card upon which graphics and/or text may be displayed for viewing. The card is comprised of integrated bottle flaps that enable adhesion and/or attachment by means to a cylindrical form and 2) the creation of an central window within the confines of the greeting card through which the label of the bottle becomes viewable when the greeting card is attached to the bottle, when otherwise the label on the bottle would be hidden or rendered out of view without said central window.